01 — At a Glance
The Prescription Powerhouse With a Walking-Dead Valuation
- 52-Week High / Low₹37,000 / ₹26,000
- FY25 Revenue (Full Year)₹6,409 Cr
- FY25 PAT (Full Year)₹1,414 Cr
- Full-Year EPS (FY25)₹665.64
- TTM EPS₹717.27
- Book Value₹1,888
- Price to Book14.5x
- Dividend Yield1.74%
- Debt / Equity0.05x
- Working Capital Days97 days
Quick Reality Check: Abbott India posted ₹717 EPS (TTM), ₹6,409 Cr revenue (FY25), and 46.2% ROCE — which means they’re running money-printing presses in their warehouse in Goa. But the stock trades at 38.1x P/E (vs. Nifty 50 at ~27x), and working capital management has deteriorated from -8 days (cash positive) to 97 days (cash bleeding). The Novo Nordisk semaglutide deal announced Feb 27, 2026 is a massive strategic coup. But is paying 40% above market for a pharma compounder in a 14% earnings growth market rational? Let’s find out.
02 — Introduction
Abbott: The Boring Blockbuster Pharma That Just Got Exciting
Abbott India Ltd has spent 82 years — yes, 1944 to 2026 — doing something genuinely remarkable: selling branded medicines profitably, without drama, without scandal, without trying to become a blockchain startup. They sell antibiotics, pain relievers, women’s health products, gastro medicines, and vaccines to millions of Indians through a network so deep, you can probably buy Abbott products at your neighbourhood chai stall.
The company has 125+ products across 11 therapeutic areas. Seven brands rank in the top 100 Indian pharma brands. One brand — Duphaston (dydrogesterone for women’s health) — commands a 75% market share in its category. That’s not market leadership. That’s market hegemony. For context, the most powerful Indian consumer brand struggles to maintain 60% share in anything. Abbott does it in a category that literally changes lives.
On February 27, 2026 — literally two weeks before this analysis — Abbott inked a non-exclusive commercial agreement to distribute Novo Nordisk’s semaglutide (Ozempic/Saxenda) across India. That’s the GLP-1 receptor agonist that turned TikTok influencers into doctors. That’s the weight-loss drug that’s expanding faster than any pharma product since Lipitor. And now, Abbott gets to distribute it. In India. Where obesity is hitting metro populations like a fat tax.
Q3 FY26 showed exactly what consistency looks like: ₹1,724 Cr quarterly sales (6.8% YoY), ₹376 Cr PAT (+4.2% YoY), ₹176.93 EPS. The profit growth is slower than industry average. But the cash generation is fortress-like. And the valuation is doing aerobics — P/E at 38.1x has barely budged despite the Ozempic news. Let’s dissect it.
Board Mood (Feb 2026): New Managing Director Kartik Rajendran (appointed June 2025) is settling in. New CFO Maithilee Mistry (appointed April 2025). The company is clearly in transition mode, fortifying the management bench for what looks like a strategic growth phase. Management turnover at 81-year-old blue-chip pharma usually means something big is brewing.
03 — Business Model: Selling Health At Premium Markups
They Don’t Make Anything. They Sell Everything.
Abbott India’s business model is almost unfairly elegant. The parent, Abbott Laboratories USA, invents molecules globally. Abbott India takes those molecules (sometimes modified for Indian regulatory requirements), manufactures some locally in Goa (14% of sales), contracts out the rest to third-party manufacturers, and sells via a sprawling network of 3,250+ sales colleagues and 6,000+ distributor touchpoints. Revenue comes from pharma products (majority), nutrition, and diagnostics — but it’s pharma that drives the bus.
The distribution network reaches millions of retailers across India. The sales force is embedded in every hospital, clinic, and doctor’s chamber. When a cardiologist writes a prescription in Delhi, there’s an Abbott rep there the same afternoon discussing why their lipid-lowering agent is marginally superior to the competitor’s. It’s not high-touch anymore — it’s just touch everywhere.
The business operates at ~26% operating margins and 27% PAT margins — almost unheard of for a branded generics compounder in India. But that’s what happens when you have 80+ years of trust embedded in the physician’s brain. Your brand literally is the quality assurance.
Women’s HealthCategory LeaderDuphaston 75% share
Field Force2,622Sales colleagues
Top 100 Brands7Pharma IPM
Goa Plant14%Sales contribution
Premium for Quality: Abbott’s P/B ratio is 14.5x because the market believes their drugs actually work better than Rs. 15 tablets from sketchy manufacturers. Is it true? Probably 70% psychosomatic, 30% actually chemistry. But in pharma, perception = profits.
💬 Here’s a thought: If Ozempic becomes mainstream in India, and Abbott distributes it through their pharma channels, will their legacy antibiotic sales get cannibalized by people switching to “rich world” drugs? Or is India big enough for both narratives?
04 — Financials Overview
Q3 FY26: The Quarterly Numbers
Result type: Quarterly Results (Dec 31, 2025) | Q3 FY26 EPS: ₹176.93 | Annualised EPS (Q3×4): ₹707.72 | Full-year FY25 EPS: ₹665.64 | TTM EPS: ₹717.27
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,724 | 1,614 | 1,757 | +6.8% | -1.9% |
| Operating Profit | 463 | 436 | 502 | +6.2% | -7.8% |
| OPM % | 27% | 27% | 29% | Flat | -200 bps |
| PAT | 376 | 361 | 415 | +4.2% | -9.4% |
| EPS (₹) | 176.93 | 169.78 | 195.43 | +4.2% | -9.4% |
The Slowdown Story: Abbott’s Q3 profit growth is stuck at 4.2% YoY — that’s below 10-year pharma CAGR of 10%. Yes, profit growth is slowing from the 18–21% range seen historically. The sequential picture is worse: Q3 revenue is down 1.9% from Q2. This is what happens when a ₹6.4k-crore company hits a scale ceiling. The company is transitioning from volume-led growth to margin + mix + new launches. The Ozempic deal is their answer to the growth stagnation question. But it’s a long-dated story — probably 2–3 years before semaglutide contributes meaningfully to consolidated sales.
05 — Valuation: Fair Value Range
What’s This Pharma Premium Actually Worth?
Join 10,000+ investors who read this every week.
